FDA approval for VK2809 by end of 2024? | Binary | | | 7 months ago | |
Viking Therapeutics' stock price up 20% by end of Q3 2024? | Binary | | | 7 months ago | |
Next major therapeutic area for Viking Therapeutics by mid-2024? | Categorical | | | 7 months ago | |
Leading market share in NASH treatments by end of 2024? | Categorical | | | 7 months ago | |
Phase 3 trial announcement for VK2809 by end of Q1 2024? | Binary | | | 7 months ago | |
Will FDA approve Wegovy for MASH treatment by end of 2025? | Binary | | | 2 months ago | |
Will Madrigal achieve $30M in Rezdiffra sales in Q3 2024? | Binary | | | 5 months ago | |
Will Madrigal secure >70% coverage for Rezdiffra by end of Q4 2024? | Binary | | | 5 months ago | |
Which drug will lead the MASH treatment market by end of 2025: Wegovy or Rezdiffra? | Categorical | | | 2 months ago | |
Will Wegovy's label be updated to include MASH treatment by end of 2025? | Binary | | | 2 months ago | |
Will Novo Nordisk release new data on Wegovy's impact on liver fibrosis by mid-2025? | Binary | | | 2 months ago | |
What will be the FDA's decision on Wegovy for MASH treatment by end of 2025? | Categorical | | | 2 months ago | |
Which drug will be more effective for MASH by end of 2025: Wegovy or Rezdiffra? | Categorical | | | 2 months ago | |
When will the EMA approve Rezdiffra? | Categorical | | | 5 months ago | |
What percentage of commercial patients will have coverage for Rezdiffra by end of Q4 2024? | Categorical | | | 5 months ago | |
What will be the net sales of Rezdiffra in Q4 2024? | Categorical | | | 5 months ago | |
Will Madrigal reduce Rezdiffra prescription fill time to 30 days by end of Q3 2024? | Binary | | | 5 months ago | |
NASH resolution percentage in Phase 3 trial for VK2809 by end of 2025? | Categorical | | | 7 months ago | |
